ホーム › 乳がん › コロラド州

コロラド州における乳がんの臨床試験

コロラド州内の拠点で、乳がんに関する53件の研究が参加者を募集しています。

コロラド州内の都市

公式研究テキスト（英語）

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Rocky Mountain Cancer Center, Denver

被験者募集中第1/2相

12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Rocky Mountain Cancer Centers, Denver

被験者募集中第3相

18歳〜100歳 · 全性別 · 2026/10/02更新 · NCT05827081

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Rocky Mountain Regional VA Medical Center, Aurora
UCHealth University of Colorado Hospital, Aurora
Penrose-Saint Francis Healthcare, Colorado Springs
他15件

被験者募集中観察研究健康なボランティア歓迎

40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069

A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

University of Colorado Denver - School of Medicine - Anschutz Medical Campus, Aurora

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/10/01更新 · NCT07701941

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Rocky Mountain Cancer Centers, Denver

被験者募集中第2相

18歳以上 · 全性別 · 2026/10/01更新 · NCT07102381

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

University of Colorado School of Medicine, Aurora

被験者募集中第2相

18歳以上 · 全性別 · 2026/10/01更新 · NCT06369285

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Sarah Cannon Research Institute (Scri) At Health One, Denver

被験者募集中第1相

18歳以上 · 全性別 · 2026/09/28更新 · NCT06120283

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

St. Marys Hospital and Regional Medical Center-SCL Health Cancer Centers of Colorado ( Site 0021), Grand Junction

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/28更新 · NCT07060807

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Intermountain Health Cancer Center Saint Joseph ( Site 0062), Denver
Rocky Mountain Cancer Centers (RMCC) ( Site 8006), Denver
Intermountain Health St. Mary's Regional Hospital ( Site 0054), Grand Junction

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/25更新 · NCT06966700

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

University of Colorado Anschutz Medical Campus ( Site 0061), Aurora
UCHealth Cherry Creek Medical Center ( Site 0094), Denver

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/25更新 · NCT06312176

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

University of Colorado Anschutz Medical Campus, Aurora
UCHealth Cherry Creek Medical Center, Denver
UCHealth Highlands Ranch Hospital, Highlands Ranch

被験者募集中第3相

60歳以上 · 全性別 · 2026/09/25更新 · NCT06377852

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Research Site, Aurora
Research Site, Denver

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/25更新 · NCT06103864

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

Saint Joseph Hospital - Cancer Centers of Colorado, Denver
Lutheran Hospital - Cancer Centers of Colorado, Golden
Saint Mary's Regional Hospital - Cancer Centers of Colorado, Grand Junction

被験者募集中第2相

18歳以上 · 全性別 · 2026/09/25更新 · NCT07007559

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Clinical Trial Site, Aurora
Clinical Trial Site, Denver

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/23更新 · NCT07085767

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Intermountain Health, Grand Junction

被験者募集中

18歳以上 · 全性別 · 2026/09/23更新 · NCT07214532

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

UCHealth Harmony, Fort Collins
Cancer Centers of Colorado St. Mary's Regional Hospital, Grand Junction
Banner MD Anderson Cancer Center at North Colorado Medical Center, Greeley
他1件

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/22更新 · NCT07174336

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

Banner MD Anderson Cancer Center at North Colorado Medical Center, Greeley
Banner MD Anderson Cancer Center at McKee Medical Center, Loveland

被験者募集中第2相

18歳以上 · 女性 · 2026/09/22更新 · NCT07287098

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

St. Joseph Hospital-Cancer Centers of Colorado, Denver
Rocky Mountain Cancer Centers, LLP, Lone Tree
AHMG Hematology and Oncology, Parker

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/15更新 · NCT06492616

A Phase 1/1b Study of IAM1363 in HER2 Cancers

University of Colorado Cancer Center, Aurora

被験者募集中第1相

18歳以上 · 全性別 · 2026/09/09更新 · NCT06253871

Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence

Outpatient CTRC, Aurora
University of Colorado Cancer Center, Aurora

被験者募集中第1相

21歳以上 · 女性 · 2026/09/04更新 · NCT06430541

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Skin Cancer Institute, Englewood

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/09/04更新 · NCT07287917

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Rocky Mountain Cancer Centers, LLP, Longmont

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/03更新 · NCT06982521

The Vanguard Study: Testing a New Way to Screen for Cancer

Keefe Memorial Hospital, Cheyenne Wells
Kaiser Permanente-Franklin, Denver
Poudre Valley Hospital, Fort Collins
他5件

被験者募集中健康なボランティア歓迎

45歳〜75歳 · 全性別 · 2026/09/02更新 · NCT06995898

Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer

Banner MD Anderson Northern Colorado, Loveland

被験者募集中第2相

18歳以上 · 全性別 · 2026/09/02更新 · NCT07076485

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

UCHealth University of Colorado Hospital, Aurora
Penrose-Saint Francis Healthcare, Colorado Springs
Rocky Mountain Cancer Centers-Penrose, Colorado Springs
他18件

被験者募集中第3相

18歳〜60歳 · 女性 · 2026/09/02更新 · NCT05879926

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

Sarah Cannon Research Institute at HealthONE, Denver

被験者募集中第1相

18歳以上 · 全性別 · 2026/08/28更新 · NCT07029399

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

Sarah Cannon Research Institute - Denver DDU, Denver

被験者募集中第1相

18歳以上 · 全性別 · 2026/08/27更新 · NCT06582017

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

Sarah Cannon Research Institute (SCRI) at HealthONE-Denver, Denver

被験者募集中第1相

18歳以上 · 全性別 · 2026/08/26更新 · NCT07383506

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

University Of Colorado Hospital - Anschutz Cancer Pavilion, Aurora

被験者募集中第2相

18歳以上 · 全性別 · 2026/08/21更新 · NCT06764940

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Local Institution - 0289, Aurora
Rocky Mountain Cancer Centers, Denver

被験者募集中第2/3相

18歳以上 · 全性別 · 2026/08/10更新 · NCT06926868

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Rocky Mountain Cancer Centers, Denver

被験者募集中第3相

18歳〜100歳 · 全性別 · 2026/08/06更新 · NCT05232916

E-Mindfulness Approaches for Living After Breast Cancer

UCHealth University of Colorado Hospital, Aurora
UCHealth Memorial Hospital Central, Colorado Springs
Memorial Hospital North, Colorado Springs

被験者募集中第3相

18歳〜50歳 · 全性別 · 2026/08/04更新 · NCT06748222

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Rocky Mountain Cancer Center, Littleton

被験者募集中第2相

18歳以上 · 全性別 · 2026/07/10更新 · NCT06695845

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

University of Colorado Cancer Center, Aurora

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/07/07更新 · NCT05768139

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

Rocky Mountain Cancer Centers, Lone Tree

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/07/02更新 · NCT07558733

Integrated Cancer Repository for Cancer Research

Advent Health, Greenwood Village

被験者募集中観察研究健康なボランティア歓迎

19歳〜110歳 · 全性別 · 2026/06/29更新 · NCT02012699

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

University of Colorado Anschutz Medical Campus ( Site 0057), Aurora

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/05/22更新 · NCT06686394

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Rocky Mountain Cancer Centers LLP, Aurora
Rocky Mountain Cancer Centers LLP, Boulder
Rocky Mountain Cancer Centers LLP, Centennial
他10件

被験者募集中第3相

18歳以上 · 全性別 · 2026/05/06更新 · NCT07062965

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Sarah Cannon Research Institute, Denver

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/05/06更新 · NCT06239194

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

University of Colorado Cancer Center, Aurora

被験者募集中第2相

18歳以上 · 全性別 · 2026/05/06更新 · NCT01042379

ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。